Abbott Laboratories (ABT) has recently received Food and Drug Administration (“FDA”) approval for its Tendyne transcatheter mitral valve replacement (“TMVR”) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (“MAC”).The Tendyne system expands the company’s comprehensive Structural Heart portfolio. ABT Stock’s Likely Trend Following the NewsAfter the announcement, Abbott shares edged up 1.3%, finishing at $132.94 yesterday. The comp ...